Peptidomimetics and small molecules as drug candidates
The peptide experts
With its technology platform Peptides-to-Drugs (P2D) the biotechnology company pursued disease indications for which limited, inadequate, or no treatment options exist, most notably within the ophthalmology, oncology and inflammatory therapeutic areas.
bmp Ventures Team
Exited (2005 – IPO)